Table 6.
Demographic characteristics of the longitudinal EDSS-lipidomics cohort
| Characteristic | Whole cohort (n=185) | Stable group (n=115) | Group with disability progression (n=70) | p value (stable vs. progressing) |
|---|---|---|---|---|
| Age (years), mean (SD) | 44.8 (11.8) | 44.0 (11.9) | 46.1 (11.6) | 0.25a |
|
|
||||
| Female Sex, n (%) | 135 (73%) | 93 (81%) | 42 (60%) | 0.002 b |
|
|
||||
| Race, n (%) | 0.036 c | |||
| Caucasian American | 152 (82%) | 96 (83%) | 56 (80%) | |
| African American | 23 (12%) | 10 (9%) | 13 (19%) | |
| Other | 10 (5%) | 9 (8%) | 1 (1%) | |
|
|
||||
| MS subtype, n (%) | <0.001 b | |||
| RRMS | 118 (64%) | 90 (78%) | 28 (40%) | |
| PMS | 67 (36%) | 25 (22%) | 42 (60%) | |
|
|
||||
| DMT at baseline d | ||||
| None | 27 (15%) | 13 (11%) | 14 (20%) | |
| High potency | 67 (36%) | 39 (34%) | 28 (40%) | |
| Intermediate potency | 6 (3%) | 3 (3%) | 3 (4%) | |
| Low potency | 79 (43%) | 56 (49%) | 23 (33%) | |
| Other | 6 (3%) | 4 (3%) | 2 (3%) | |
|
|
||||
| EDSS at baseline, median (IQR) | 3 (2-6) | 2.5 (1.5-5) | 3.5 (2-6) | 0.11e |
|
|
||||
| Disease duration (years), median (IQR) | 9 (6-15) | 9 (6-14) | 10 (6-17) | 0.24e |
|
|
||||
| Follow-up (years), median (IQR) | 5.0 (4.6-5.3) | 5.0 (4.6-5.3) | 4.9 (4.7-5.3) | 0.54e |
a
Student’s t-test
b
Chi-square test
c
Fisher’s exact test
d
Glatiramer acetate, interferon-beta, and teriflunomide were classified as low-potency DMTs, dimethyl fumarate and fingolimod as intermediate-potency DMTs, and natalizumab, ocrelizumab, rituximab, alemtuzumab, and daclizumab as high-potency DMTs.
e
Wilcoxon rank-sum test
MS: Multiple Sclerosis; RRMS: Relapsing-Remitting MS; PMS: Progressive MS; SD: Standard Deviation; DMT: Disease Modifying Treatment; EDSS: Expanded Disability Status Scale; IQR: Interquartile range